HWI pharma services GmbH successfully passes its first FDA inspection!

The inspection was performed at HWI’s Rülzheim site on 26th and 27th November 2018 by the US Food and Drug Administration (FDA).

As a specialist for pharmaceutical services HWI performs contract analyses on drug substances and drug products which are currently undergoing marketing authorisation procedures for the US market.

The inspection was successfully passed with the result “no observations – no action indicated“. HWI pharma services GmbH at its Rülzheim site is hence FDA approved for the first time!